These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 9484822)
1. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822 [TBL] [Abstract][Full Text] [Related]
2. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide. Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227 [TBL] [Abstract][Full Text] [Related]
4. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378 [TBL] [Abstract][Full Text] [Related]
5. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281 [TBL] [Abstract][Full Text] [Related]
7. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment. Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820 [TBL] [Abstract][Full Text] [Related]
8. [The scintigraphy of somatostatin receptors in the carcinoid tumor]. Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324 [TBL] [Abstract][Full Text] [Related]
9. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide. Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760 [TBL] [Abstract][Full Text] [Related]
11. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours. Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860 [TBL] [Abstract][Full Text] [Related]
12. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523 [TBL] [Abstract][Full Text] [Related]
13. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146 [TBL] [Abstract][Full Text] [Related]
16. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Oberg K; Eriksson B Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700 [TBL] [Abstract][Full Text] [Related]
17. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Kölby L; Wängberg B; Ahlman H; Jansson S; Forssell-Aronsson E; Erickson JD; Nilsson O Digestion; 1998; 59(2):160-6. PubMed ID: 9586830 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220 [TBL] [Abstract][Full Text] [Related]